LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Trial Profile

LUX-Lung 6: A Randomized, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Afatinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms LUX-Lung 6
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 Nov 2017 Results assessing patient-reported outcomes stratified by EGFR mutation type from two phase III studies (LUX-Lung 3 and LUX-Lung 6) published in The Patient - Patient-Centered Outcomes Research
    • 18 Oct 2017 Results of post-hoc analysis assessing the impact of afatinib dose reduction on safety, pharmacokinetics, efficacy and patient-reported outcomes in the phase III LUX-Lung 3 and 6 trials (n=229/n=239), presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results of post- hoc analysis of efficacy, safety and patient-reported outcomes (PROs) in afatinib long-term responders (LTRs) in Lux-Lung 3/6/7 presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top